In this study a strong neovascular PSMA immunoreactivity was described in many tumors, including clear cell renal cell carcinoma, colonic adenocarcinoma, glioblastoma multiforme, non-small cell lung carcinoma and breast carcinoma 86. This evidence concerns the gene FOLH1 and glioblastoma.